Motavizumab failure shifts spotlight to RSV vaccines

The news this week that AstraZeneca ($AZN) is writing off its big motavizumab program for RSV has shifted the spotlight to a slate of earlier stage compounds as well as vaccines. The Wall Street Journal notes that both Novavax and NanoBio have preclinical RSV vaccines in the works that now stand to benefit from AstraZeneca's loss.

Motavizumab was intended to replace the blockbuster RSV drug Synagis, which could lose patent protection without a branded successor from AstraZeneca to take its place. Cubist and Alnylam have a mid-stage drug program in place and the early-stage vaccine programs could be worth substantially more in a licensing deal.

But don't write off AstraZeneca yet. Its researchers are also pursuing two Phase I/II trials for new RSV vaccines, giving them a lead in that development race.

- here's the report from the Wall Street Journal

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.